

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-47 (cancelled).

Claim 48 (withdrawn). A method of producing a peptide of from about 8 to about 25 amino acids and having a sequence contained within amino acid residues 61-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide is capable of neutralizing or modulating the production of anti-myelin basic protein, comprising expressing a DNA encoding the peptide in a host cell and isolating the peptide produced by the host cell.

Claim 49 (withdrawn). The method of claim 27, wherein the DNA encodes a sequence contained within amino acid residues 75-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide is capable of neutralizing or modulating the production of anti-myelin basic protein.

Claim 50 (withdrawn). The method of claim 27, wherein the DNA encodes a sequence contained within amino acid residues 80-97 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide is capable of neutralizing or modulating the production of anti-myelin basic protein.

Claim 51 (withdrawn). The method of claim 27, wherein the DNA encodes a sequence contained within amino acid residues 82-99 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide is capable of neutralizing or modulating the production of anti-myelin basic protein.

Claim 52 (withdrawn). The method of claim 27, wherein the DNA encodes a sequence contained within amino acid residues 84-93, 85-94, 86-95, or 87-96 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide is capable of neutralizing or modulating the production of anti-myelin basic protein.

Claim 53 (withdrawn). The method of claim 27, wherein the DNA encodes a sequence contained within amino acid residues 91-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide is capable of neutralizing or modulating the production of anti-myelin basic protein.

Claim 54 (withdrawn). The method of claim 27, wherein the DNA encodes a sequence contained within amino acid residues 75-95 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide is capable of neutralizing or modulating the production of anti-myelin basic protein.

Claim 55 (withdrawn). The method of claim 27, wherein the DNA encodes a sequence contained within amino acid residues 64-78 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide is capable of neutralizing or modulating the production of anti-myelin basic protein.

Claims 56-68 (cancelled).

Claim 69 (previously presented). A method of reducing free anti-myelin basic protein in a patient in need thereof by administering to said patient an effective amount of a peptide of from about 8 to about 25 amino acids and having a sequence contained within amino acid residues 61-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 70 (previously presented). The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 75-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 71 (previously presented). The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 80-97 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 72 (previously presented). The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 82-99 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 73 (previously presented). The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 84-93, 85-94, 86-95, or 87-96 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 74 (previously presented). The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 91-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 75 (previously presented). The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 75-95 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 76 (previously presented). The method of Claim 69 wherein the peptide has a sequence contained within amino acid residues 64-78 of SEQ ID NO:1, including substitutions, additions or deletions thereof, provided that said peptide can reduce free anti-myelin basic protein.

Claim 77 (previously presented). The method of Claim 69 wherein the peptide is administered in admixture with a pharmaceutical acceptable carrier.

Claim 78 (previously presented). The method of Claim 69 wherein the peptide is administered intravenously or intrathecally, or in combination.

Claim 79 (previously presented). The method of Claim 69 wherein the peptide is administered as a single or sequential dose.

Claim 80 (previously presented). The method of Claim 69 wherein the patient has chronic progressive MS.

Claim 81 (previously presented). The method of Claim 69 wherein the patient has an acute MS relapse.

Claim 82 (new). A method of treating multiple sclerosis in a patient in need thereof by administering to said patient an effective amount of a peptide of from about 8 to about 25 amino acids having a sequence contained within amino acid residues 61-106 of SEQ ID NO:1, wherein the peptide does not comprise amino acid residues 87-93 of SEQ ID NO: 1, including

substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 83 (new). The method of Claim 82 wherein the peptide has a sequence contained within amino acid residues 64-78 of SEQ ID NO:1, including substitutions, additions or deletions thereof, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 84 (new). The method of Claim 82 wherein the peptide has a sequence contained within amino acid residues 61-75 of SEQ ID NO:1, including substitutions, additions or deletions thereof, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 85 (new). The method of Claim 82 wherein the peptide has a sequence contained within amino acid residues 69-83 of SEQ ID NO:1, including substitutions, additions or deletions thereof, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 86 (new). The method of Claim 82 wherein the peptide has a sequence contained within amino acid residues 91-106 of SEQ ID NO:1, including substitutions, additions or deletions thereof, including substitutions, additions or deletions thereof, provided that said peptide can neutralize or modulate the production of anti-myelin basic protein.

Claim 87 (new). The method of Claim 82 wherein the peptide is administered in admixture with a pharmaceutical acceptable carrier.

Claim 88 (new). The method of Claim 82 wherein the peptide is administered intravenously or intrathecally, or in combination.

Claim 89 (new). The method of Claim 82 wherein the peptide is administered as a single or sequential dose.

Claim 90 (new). The method of Claim 82 wherein the patient has chronic progressive MS.

Claim 91 (new). The method of Claim 82 wherein the patient has an acute MS relapse.